Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genocea Biosciences (GNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,245
  • Shares Outstanding, K 86,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,710 K
  • 36-Month Beta 1.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.31
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.71
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/01/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.14
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +70.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.56 +3.57%
on 11/28/18
0.76 -24.18%
on 11/08/18
-0.14 (-19.44%)
since 11/07/18
3-Month
0.49 +18.37%
on 09/18/18
0.88 -34.09%
on 10/05/18
-0.02 (-3.01%)
since 09/07/18
52-Week
0.49 +18.37%
on 09/18/18
1.39 -58.27%
on 12/27/17
-0.52 (-47.27%)
since 12/07/17

Most Recent Stories

More News
Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Genocea Biosciences, Inc....

MIME : 33.99 (-7.33%)
BIG : 31.00 (-23.08%)
CONN : 23.73 (-5.04%)
GNCA : 0.58 (-2.19%)
SEMG : 16.18 (+2.53%)
NEOS : 2.00 (-1.48%)
Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances in Personalized Cancer Immunotherapies

Event to be webcast live at 12 pm ET

GNCA : 0.58 (-2.19%)
Genocea Unveils Possible Mechanism for Tumor Resistance to Immunotherapy at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

ATLAS(TM)-identified "inhibitory" neoantigens promote tumor growth in mouse model

GNCA : 0.58 (-2.19%)
Genocea Biosciences: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $7.8 million in its third quarter.

GNCA : 0.58 (-2.19%)
Genocea Reports Third Quarter 2018 Financial and Operating Results

Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patients

GNCA : 0.58 (-2.19%)
Genocea to Host Third Quarter 2018 Financial Results Conference Call & Webcast on November 1, 2018 at 9:00 a.m. ET

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday,...

GNCA : 0.58 (-2.19%)
Analysis: Positioning to Benefit within Genocea Biosciences, Retail Properties of America, Hawkins, QUANTENNA COMMS, Hillenbrand, and Herman Miller -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Genocea Biosciences, Inc....

RPAI : 12.82 (-0.31%)
HWKN : 39.89 (+0.13%)
QTNA : 14.69 (-2.07%)
HI : 40.78 (-2.70%)
GNCA : 0.58 (-2.19%)
MLHR : 32.08 (-2.20%)
Genocea Announces Upcoming Presentations at SITC 2018

Posters showcase ability of ATLAS(TM) platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies

GNCA : 0.58 (-2.19%)
Genocea Strengthens Leadership Team: Thomas Davis, M.D. Appointed Chief Medical Officer; Derek Meisner, J.D. Joins as General Counsel

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two additions to its leadership team: Thomas Davis, M.D. as Chief Medical...

GNCA : 0.58 (-2.19%)
Genocea Biosciences: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $15.3 million in its first quarter.

GNCA : 0.58 (-2.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade GNCA with:

Business Summary

Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections,...

See More

Key Turning Points

2nd Resistance Point 0.63
1st Resistance Point 0.61
Last Price 0.58
1st Support Level 0.57
2nd Support Level 0.55

See More

52-Week High 1.39
Fibonacci 61.8% 1.05
Fibonacci 50% 0.94
Fibonacci 38.2% 0.83
Last Price 0.58
52-Week Low 0.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar